Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

By K. Blanc, F. Frassoni, L. Ball, F. Locatelli, H. Roelofs, I. Lewis, E. Lanino, B. Sundberg, M. E. Bernardo, M. Remberger and 2 more. The Lancet, 2008

2,582 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/70b177d5fff7d554394f7e09b9e999574b67124e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. A. Keating
2. Jaehyup Kim
3. P. Hematti
4. W. Fibbe
5. M. Kwa
6. C. Herberts
7. A. Caplan
8. H. Hermsen

In Hematology

1. W. Fibbe
2. A. Keating
3. A. Caplan

In Pulmonary and Respiratory Medicine

1. W. Fibbe
2. A. Caplan

Citations in the corpus

• Risk factors in the development of stem cell therapy (2011, background): “In vivo control or limitation of GVHD by MSC has been reported both in humans [93] and animal models [81,83].”
• Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials (2012, background): “[20,27,29,31,34,39,43] Twenty-seven of the 36 studies cultured the MSCs in fetal bovine serum, [11–17,19– 27,30,31,33–35,38–40,42,43,46] five in human serum, [28,29,32, 37,45] and four did not report the source of serum used.”
• Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC (2011, background): “In a recent phase II study, GvHD in humans could be ameliorated upon hematopoietic stem cell transplantation (HSCT) [ 99 ] and it was found that MSC expand in vivo irrespective of the donor as MSC from HLA-identical sibling donors, haploidentical donors, and third-party HLA-mismatched donors were eq”
• Mesenchymal Stem Cells Secrete Immunologically Active Exosomes (2014, neutral): “MSCs induced complete responses in 55% of 55 patients with acute GVHD grade 2–4, and this response was not dependent on the immune compatibility between the donor MSCs and the recipients [1].”
• Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells (2012, positive): “Moreover, both haploidentical and third-party (HLA-mismatched) BMMSCs can be safely and effectively used to treat de novo and steroid-resistant acute GvHD [118,200,202–205].”
• Mesenchymal stromal cells: new directions. (2012, background): “…6 protein (TSG6) is an immunosuppressive molecule produced by MSCs 712 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. that partially recapitulates the hemodynamic improvement after intravenous infusion of the cells following experimental acute myocardial infarction in mice (Lee et al., 2009).”
• Mesenchymal stromal cells: sensors and switchers of inflammation. (2013, neutral): “…homeostasis serves as the basis for their application in disorders resulting from autogeneic or allogeneic immune responses, including Graft-versus- Host Disease (GvHD) and autoimmune disorders (Le Blanc et al., 2008; Duijvestein et al., 2010) and can be referred to as ''stromal cell therapy.''”
• Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study (2010, background): “Furthermore, in humans, transplantation of bone marrow (bm) derived MSCs has led to improvement of corticoid refractory graft versus host disease (GvHD), including GvHD of the gut”